Understanding the landscape and key trends helps stakeholders—from manufacturers to policymakers and patient groups—navigate requirements and support better outcomes.
Core organizations and frameworks
International oversight relies on a network of authorities and harmonization bodies. The World Health Organization offers guidance and a prequalification program that helps low- and middle-income countries evaluate product quality.
Regional regulators and stringent national agencies set standards that many others adopt by reference. Harmonization initiatives provide common technical requirements for quality, safety and efficacy, reducing duplication and speeding reviews across markets.
Regulatory reliance and convergence
Regulatory reliance—where regulators use assessments from recognized counterparts—has become an essential tool to increase regulatory efficiency and improve access.
Convergence of standards through shared guidelines enables faster approvals while maintaining safety. For manufacturers, reliance pathways reduce repetitive dossier requirements and inspection burdens. For regulators with limited resources, reliance and mutual recognition strengthen oversight capacity without compromising public health.
Quality assurance and supply chain resilience
Good Manufacturing Practice (GMP) compliance, serialization and track-and-trace systems are central to preventing counterfeit medicines and ensuring product integrity across global supply chains. Diversifying active pharmaceutical ingredient (API) sources and investing in local production capabilities bolster resilience against disruptions. Remote and hybrid inspection models have broadened oversight reach, though they require robust data integrity and traceability practices to be effective.
Pharmacovigilance and real-world evidence
Post-market safety surveillance is a shared international responsibility. Enhanced pharmacovigilance systems, combined with real-world evidence from electronic health records and registries, enable faster detection of adverse events and inform regulatory action. Global signal-sharing platforms and common reporting standards accelerate communication between authorities, helping to protect patients everywhere.
Emerging modalities and evolving regulation
Biologics, biosimilars, gene therapies and digital therapeutics present novel regulatory challenges. Biosimilar approval frameworks and interchangeability criteria differ across jurisdictions, underscoring the need for harmonized scientific approaches. Software as a medical device (SaMD) demands agile regulatory models that incorporate cybersecurity, continuous updates and real-world performance monitoring. Regulators are adapting by issuing guidance on evidence expectations and lifecycle-based oversight.
Access, affordability and intellectual property
Drug regulation intersects with policies on pricing, patent protection and procurement. Regulatory pathways that support generic competition, such as expedited approvals and transparent exclusivity rules, contribute to affordability. Prequalification and pooled procurement mechanisms can expand access in resource-limited settings, while regulatory safeguards address substandard and falsified products.
Best practices for stakeholders
– Adopt reliance and expedited pathways when appropriate to accelerate access without sacrificing safety.
– Invest in pharmacovigilance infrastructure and data interoperability to enable timely safety actions.
– Implement serialization and robust supply chain tracking to combat counterfeits and improve recall efficiency.
– Engage with regulators early, particularly for advanced therapies and digital products, to clarify evidence expectations.
– Support capacity-building and technical cooperation to strengthen global regulatory systems and harmonize standards.
Regulatory systems must remain adaptive as science and markets evolve. Prioritizing transparency, collaboration and data-driven decision-making enhances public trust and ensures that safe, effective medicines reach patients more quickly and reliably across borders.
